Evogene (NASDAQ:EVGN) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research report sent to investors on Tuesday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital dropped their target price on Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, August 23rd.

Evogene Stock Performance

Shares of NASDAQ:EVGN opened at $1.69 on Tuesday. Evogene has a 52-week low of $1.44 and a 52-week high of $10.40. The company has a market capitalization of $9.06 million, a PE ratio of -0.38 and a beta of 1.43. The company has a fifty day moving average of $2.27 and a 200-day moving average of $4.29.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC acquired a new stake in Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Hedge funds and other institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.